Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome

Avizorex Pharma, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye with a new mechanism of action currently undergoing late-stage preclinical studies. Avizorex Pharma is an ophthalmology biotech backed by Inveready Venture Capital with headquarters in Elche (Alicante, Spain) and offices in the Parc Científic de Barcelona (PCB).

The patent to be issued from this allowed application covering an invention from Spanish leading neuroscience center Instituto de Neurociencias de Alicante (IN) and exclusively licensed to Avizorex carries a patent term to at least 2031, and represents a significant addition in Avizorex current patent portfolio. The company will continue prosecuting the patent application in other jurisdictions.

“This is a very significant milestone that strengthens our IP position and paves the way to aggresively continue building a solid IP portfolio around our inventions and products in the area of Dry Eye Syndrome”, said Patrick Tresserras, Avizorex Founder and CEO. “We are looking forward to expanding our patent portfolio as we further investigate the safety and efficacy profile of AVX-012”.

Avizorex Pharma, a spin-off of Miguel Hernández University, was founded in 2013 on the grounds of neurobiological research performed by the Group on Ocular Sensory Innervation led by Prof. Carlos Belmonte at the Instituto de Neurociencias de Alicante and studies novel pharmacological approaches to treat chronic dry eye.